Business Wire

City of Oulu: Finland’s Largest Hydrogen Refining Plant One Step Closer to Starting Sustainable Aviation Fuel Production

13.2.2025 19:30:00 EET | Business Wire | Press release

Share

The City of Oulu, Finland, and French company Verso Energy have signed a co-operation agreement aiming to build a hydrogen processing plant in Oulu. Verso Energy intends to construct a plant with a yearly production capacity of 80 000 tonnes of e-SAF. The estimated value of the project is €1.4 billion, and it is expected to create 250 jobs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213216649/en/

The City of Oulu, Finland, and French company Verso Energy have signed a co-operation agreement at the Northern Power forum aiming to build a hydrogen processing plant in Oulu. Signing the agreement strengthens the City of Oulu’s status as a key hydrogen hub in the Nordics. Verso Energy’s plant in the port area of Oulu will be the largest of its kind in Finland so far. In the picture from left to right: Ari Alatossava, Mayor of Oulu, Antoine Huard, CEO of Verso Energy and Marko Mykkänen, CEO, Port Of Oulu. (Photo: City of Oulu)

Signing the agreement strengthens the City of Oulu’s status as a key hydrogen hub in the Nordics. Verso Energy’s plant in the port area of Oulu will be the largest of its kind in Finland so far.

Antoine Huard, CEO of Verso Energy, stated at the Northern Power forum in Oulu that the biggest city within the Arctic region has everything it takes to produce emission-free aviation fuel in an environmentally friendly way.

“Finland is a very attractive country for e-SAF production, and the Oulu site has all the qualities to be a very competitive site at the European level,” Huard says.

“Successful collaboration with the City and Port of Oulu has been key to the project's development, showcasing Finland's potential to combine job creation, industrial growth, and sustainability,” he adds.

Verso Energy has several hydrogen and synthetic fuel plants in pipeline in France, but the plant being planned for Oulu, is among the company’s first projects abroad. Verso Energy offers synthetic fuels for both aircraft and ships.

Starting this year, fuel used at the EU's largest airports must include a 2% blend of sustainable aviation fuel (SAF). Currently, there are no SAF production plants in Finland.

The agreement ensures that the City of Oulu will advance the zoning of the Port of Oulu’s green transition industrial area, aligning the requirements and goals of both the Verso Energy and the city.

Marko Kilpeläinen, Director of Urban Environment Services for the City of Oulu, highlights fluent co-operation as Finland’s strength in attracting green transition investments.

"In Finland, the zoning process can run parallel to a company's project planning, offering more flexibility compared to some other countries," Kilpeläinen points out.

The co-operation agreement remains in effect until the end of 2026, during which both parties work toward the implementation agreement, defining threshold investments and the division of responsibilities.

"I am glad that Verso's project has progressed so smoothly. This indicates that our city has a valuable role to play in the green transition. I want to thank our experts for their efforts so far and Business Finland for facilitating the contact with Verso Energy,” says Ari Alatossava, Mayor of Oulu.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213216649/en/

Contacts

Media Contacts for further inquiries:

Verso Energy:
Ms. Stéphanie Lefebvre-Oustry
slefebvre@aromates.fr
+33 6 11 47 48 83

City of Oulu:
Mr. Marko Kilpeläinen
Director of Urban Environment Services
marko.kilpelainen@ouka.fi
+358 40 5133650

BusinessOulu:
Mr. Janne Hietaniemi
Key Account Director
janne.hietaniemi@businessoulu.com
+358 40 649 1211

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release

The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release

Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye